Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.8527
Abstract: 8527Background: Maintenance therapy delays disease progression in non-ASCT NDMM patients. However, in practice, currently used maintenance therapies may be limited to fixed duration due to toxicity... read more here.
Keywords: ixazomib placebo; maintenance; ndmm patients; placebo maintenance ... See more keywords
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10102535
Abstract: In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD).… read more here.
Keywords: bone marrow; plasma cells; patients plasmacytomas; multiple myeloma ... See more keywords
Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14246106
Abstract: Simple Summary Extramedullary relapse of multiple myeloma (MM) is often resistant to existing treatments, and has an extremely poor prognosis. Therefore, early identification of high-risk extramedullary relapse patients has important clinical significance. However, due to… read more here.
Keywords: risk extramedullary; high risk; relapse; extramedullary relapse ... See more keywords